ERC Consolidator Grant · 2025
Alpha Nanotherapy to Target Metastatic Cancer
Targeted alpha therapy, a treatment that relies on targeting pharmaceuticals labeled with ⍺ emitters, has produced complete cures of metastatic cancer patients with refractory diseases in clinical trials. However, targeted alpha therapy is limited by the release of radioisotopes from the pharmaceuticals. In ⍺ emissions, the decay products break the chemical bonds by which they are bound to the radiopharmaceutical, and once liberated, they spread all over the body, causing off-target radiopoisoning. Thus, preventing radioisotope release is a fundamental step to improve targeted alpha therapy safety and extend its use beyond terminal cases. In AlphaTar, I will completely change how ⍺ emitters…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.